Moderna | Fortjeneste Per Aksje



Fiscal Kalender Faktiske Snittforvetning Forrige Dato
FY2025Q1 Mar/2025 -3.03 -3.07 May/01 2025
FY2024Q4 Dec/2024 -2.91 -2.73 0.55 Feb/14 2025
FY2024Q3 Sep/2024 0.03 -1.92 -9.53 Nov/07 2024
FY2024Q2 Jun/2024 -3.33 -3.35 -3.62 Aug/01 2024
FY2024Q1 Mar/2024 -3.07 -3.55 0.19 May/02 2024
FY2023Q4 Dec/2023 0.55 -0.99 3.61 Feb/22 2024
FY2023Q3 Sep/2023 -9.53 -1.90 2.53 Nov/02 2023
FY2023Q2 Jun/2023 -3.62 -4.11 5.24 Aug/03 2023
FY2023Q1 Mar/2023 0.19 -1.66 8.58 May/04 2023
FY2022Q4 Dec/2022 3.61 4.57 11.29 Feb/23 2023
FY2022Q3 Sep/2022 2.53 2.47 7.7 Nov/03 2022
FY2022Q2 Jun/2022 5.24 4.44 6.46 Aug/03 2022

Eps Endring Dato
Acadia Pharmaceuticals USD 0.86 0.66 2024-12
Adcock Ingram Holdings ZAR 2.59 0.17 2024-12
Agios Pharmaceuticals USD -1.44 0.98 2024-12
Alnylam Pharmaceuticals USD -0.65 0.22 2024-12
Amgen USD 5.31 0.27 2024-12
Arrowhead Research USD -1.39 0.02 2024-12
Biogen USD 3.44 0.64 2024-12
BioMarin Pharmaceutical USD 0.64 0.09 2024-12
Celltrion KRW 395.45 36.4 2024-09
Cspc Pharmaceutical CNY 0.06 0.05 2024-09
Dianthus Therapeutics USD -0.74 0.23 2024-09
Gilead Sciences USD 1.9 0.12 2024-12
GlaxoSmithKline GBP 0.23 0.27 2024-12
Incyte USD 1.43 0.36 2024-12
Ionis Pharmaceuticals USD -0.66 0.29 2024-12
Kangmei Pharma CNY 0 0 2024-09
Knight Therapeutics CAD 0 0.02 2024-09
Laboratorios Farma 0.55 1.41 2024-06
Malin Corporation 0 0 2024-12
Moderna USD -2.91 2.94 2024-12
Organigram Holdings CAD -0.2 0.12 2024-12
Pharma Mar EUR 1.08 0.87 2024-12
Qiagen NV USD 0.59 0.06 2024-12
Regeneron Pharmaceuticals USD 12.07 0.39 2024-12
Sarepta Therapeutics USD 1.5 1.16 2024-12
Sartorius EUR 1.04 0.83 2024-12
Sino Biopharmaceutical CNY 0.08 0.04 2024-06
Tilray USD -0.1 0.05 2024-11
Ultragenyx Pharmaceutical USD -1.39 0.01 2024-12
United Therapeutics USD 6.19 0.2 2024-12
Vertex Pharmaceuticals USD 3.98 0.4 2024-12
Zhangzhou Pientzehuang Pharmaceutical 1.6 0.37 2024-09



Moderna Fortjeneste Per Aksje - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Mar 2025.